Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia.
暂无分享,去创建一个
E. Campo | A. Valera | D. Colomer | D. Costa | I. Madrigal | M. Camós | F. Cervantes | Amparo Arias | A. Carrió | M. Teixidó | J. Aguilar | Alexandra Valera
[1] H. Kantarjian,et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. , 2005, Blood.
[2] A. Tefferi,et al. Clinical correlates of submicroscopic deletions involving the ABL–BCR translocation region in chronic myeloid leukemia , 2005, European journal of haematology.
[3] W. Sanger,et al. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. , 2004, Cancer genetics and cytogenetics.
[4] A. Green,et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. , 2003, Blood.
[5] A. Green,et al. Survival implications of molecular heterogeneity in variant Philadelphia‐positive chronic myeloid leukaemia , 2003, British journal of haematology.
[6] M. Rocchi,et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients , 2002, Genes, chromosomes & cancer.
[7] L. Trakhtenbrot,et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. , 2001, Cancer genetics and cytogenetics.
[8] J. Squire,et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. , 2001, Blood.
[9] K. S. Reddy,et al. A FISH study of variant Philadelphia rearrangements. , 2000, Cancer genetics and cytogenetics.
[10] M. Leversha,et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. , 2000, Blood.
[11] S. Ben-Neriah,et al. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. , 1999, Cancer genetics and cytogenetics.
[12] F. Mitelman. ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .
[13] P. Koduru,et al. Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13. , 1993, Oncogene.
[14] C. Morris,et al. Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement? , 1991, Cancer genetics and cytogenetics.
[15] B. Johansson,et al. Cytogenetic and Molecular Genetic Evolution of Philadelphia-Chromosome-Positive Chronic Myeloid Leukaemia , 2003 .
[16] L. Campbell,et al. a powerful and independent prognostic indicator in chronic myeloid leukemia , 2001 .
[17] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .